Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
November 1, 2022
May 18, 2023
c8db4f04-043a-440b-838b-50bc0e9b17c9
Related Documents
Drug Master Files Guidance for Industry
Guidance DocumentNovember 15, 2019Center for Drug Evaluation and Research
Accelerated Approval – Expedited Program for Serious Conditions
Guidance DocumentDecember 5, 2024Center for Drug Evaluation and Research
Considerations for Rescinding Breakthrough Therapy Designation
Guidance DocumentJune 24, 2022Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.